Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis

Journal of Managed Care Pharmacy

Volumn 18, Issue 9 A, 2012, Pages 701-712

  Yen, Linnette ^a   Wu, Joanne ^b   Hodgkins, Paul ^c   Cohen, Russell D ^b   Nichol, Michael B ^d  

^a SHIRE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Sol Price School of Public Policy   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BALSALAZIDE; CORTICOSTEROID; DIPENTRUM; IMMUNOSUPPRESSIVE AGENT; MESALAZINE; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH MAINTENANCE ORGANIZATION; HOSPITAL PHARMACY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MEDICARE; PATIENT COMPLIANCE; PREDICTIVE VALUE; PREFERRED PROVIDER ORGANIZATION; RISK ASSESSMENT; SEX DIFFERENCE; TREATMENT REFUSAL; ULCERATIVE COLITIS;

EID: 84872441296     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2012.18.9.701     Document Type: Article

References (39)

1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46-54. Available at: http://download.journals.elsevierhealth.com/pdfs/journals/0016-5085/PIIS0016508511013783.pdf. Accessed November 11, 2012.
2. Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010;31(7):693-707.
3. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(Suppl 5):V1-V16. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1867788/pdf/v053p000v1.pdf. Accessed November 11, 2012.
4. Kornbluth A, Sachar DB. Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99(7):1371-85.
5. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60(5):571-607.
6. Kane SV, Robinson A. Review article: understanding adherence to medication in ulcerative colitis-innovative thinking and evolving concepts. Aliment Pharmacol Ther. 2010;32(9):1051-58.
7. Lakatos PL. Prevalence, predictors, and clinical consequences of medical adherence in IBD: how to improve it? World J Gastroenterol. 2009;15(34):4234-39. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744179/pdf/WJG-15-4234.pdf. Accessed November 11, 2012.
8. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114(1):39-43.
9. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;23(5):577-85. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2006.02809.x/pdf. Accessed November 11, 2012.
10. Bernick SJ, Kane S. Insight into the widespread problem of nonadherence to therapy in ulcerative colitis patients. Expert Rev Clin Immunol. 2010;6(4):677-82.
11. Olmstead J. Oral 5-aminosalicylic acid therapy for mild-to-moderate ulcerative colitis. J Am Acad Nurse Pract. 2010;22(11):586-92.
12. Higgins PD, Rubin DT, Kaulback K, Schoenfield PS, Kane SV. Systematic review: impact of nonadherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther. 2009;29(3):247-57. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2008.03865.x/pdf. Accessed November 11, 2012.
13. Kane SV, Brixner D, Rubin DT, Sewitch MJ. The challenge of compliance and persistence: focus on ulcerative colitis. J Manag Care Pharm. 2008;14 (1 Suppl A):S2-S12. Available at: http://www.amcp.org/data/jmcp/JMCPSuppA_Jan08.pdf.
14. Hawthorne AB, Rubin G, Ghosh S. Review article: medication nonadherence in ulcerative colitis-strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther. 2008;27(12):1157-66. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2008.03698.x/pdf. Accessed November 11, 2012.
15. Kane SV, Accortt NA, Magowan S, Brixner D. Predictors of persistence with 5-aminosalicylic acid therapy for ulcerative colitis. Aliment Pharmacol Ther. 2009;29(8):855-62. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2009.03941.x/pdf. Accessed November 11, 2012.
16. Loftus EV Jr. A practical perspective on ulcerative colitis: patients' needs from aminosalicylate therapies. Inflamm Bowel Dis. 2006;12(12): 1107-13. Available at: http://onlinelibrary.wiley.com/doi/10.1097/01.mib.0000235831.01682.8d/pdf. Accessed November 11, 2012.
17. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18(2):191-98. Available at: http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2036.2003.01648.x/pdf. Accessed November 11, 2012.
18. Dignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7(7):762-69.
19. Kruis W, Kiudelis G, Rácz I, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut. 2009;58(2):233-40. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269751/pdf/GUT-58-02-0233.pdf. Accessed November 11, 2012.
20. Sandborn WJ, Kamm MA, Lichtenstein GR, Lyne A, Butler T, Joseph RE. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2007;26(2):205-15. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2007.03361.x/pdf. Accessed November 11, 2012.
21. Kane SV, Sumner M, Solomon D, Jenkins M. Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database. Dig Dis Sci. 2011;56(12):3463-70.
22. IMS LifeLink Health Plan Claims Database. PharMetrics, Inc., a unit of IMS Health. Watertown, WA. Copyright 2010. All Rights Reserved.
23. Peterson AM, Nau DP, Cramer JA, Benner JS, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3-12. Available at: http://www.ispor.org/workpaper/research_practices/Peterson_Scientific_Report.pdf. Accessed November 11, 2012.
24. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-47. Available at: http://www.ispor.org/workpaper/research_practices/Cramer.pdf. Accessed November 11, 2012.
25. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-39.
26. Rubin DT, Siegel CA, Kane SV, et al. The impact of ulcerative colitis from patients' and physicians' perspectives: results from the UC: NORMAL survey. Inflamm Bowel Dis. 2009;15(4):581-88. Available at: http://onlinelibrary. wiley.com/doi/10.1002/ibd.20793/pdf. Accessed November 11, 2012.
27. D'Incà R, Bertomoro P, Mazzocco K, Vettorato MG, Rumiati R, Sturniolo GC. Risk factors for nonadherence to medication in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2008;27(2):166-72. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2007.03555.x/pdf. Accessed November 11, 2012.
28. Jackson CA, Clatworthy J, Robinson A, Horne R. Factors associated with nonadherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2010;105(3):525-39.
29. Cervený P, Bortlík M, Kubena A, Vlcek J, Lakatos PL, Lukás M. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis. 2007;13(10):1244-49. Available at: http://onlinelibrary. wiley.com/doi/10.1002/ibd.20189/pdf. Accessed November 11, 2012.
30. Nahon S, Lahmek P, Saas C, et al. Socioeconomic and psychological factors associated with nonadherence to treatment in inflammatory bowel disease patients: results of the ISSEO survey. Inflamm Bowel Dis. 2011;17(6):1270-76.
31. Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol. 2007;102(7):1417-26.
32. Moshkovska T, Stone MA, Clatworthy J, et al. An investigation of medication adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis, using self-report and urinary drug excretion measurements. Aliment Pharmacol Ther. 2009;30(11-12):1118-27. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2009.04152.x/pdf. Accessed November 11, 2012.
33. McWilliams JM. Health consequences of uninsurance among adults in the United States: recent evidence and implications. Milbank Q. 2009;87(2):443-94.
34. Sabik LM. The effect of community uninsurance rates on access to health care. Health Serv Res. 2012;47(3 Pt 1):897-918.
35. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105-16.
36. Choo PW, Rand CS, Inui TS, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care. 1999;37(9):846-57.
37. Nichol MB, Knight TK, Priest JL, Wu J, Cantrell CR. Nonadherence to clinical practice guidelines and medications for multiple chronic conditions in a California Medicaid population. J Am Pharm Assoc (2003). 2010;50(4):496-507.
38. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008;28(4):437-43. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2737273/. Accessed November 11, 2012.
39. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728-40.